JPWO2020160020A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160020A5 JPWO2020160020A5 JP2021543372A JP2021543372A JPWO2020160020A5 JP WO2020160020 A5 JPWO2020160020 A5 JP WO2020160020A5 JP 2021543372 A JP2021543372 A JP 2021543372A JP 2021543372 A JP2021543372 A JP 2021543372A JP WO2020160020 A5 JPWO2020160020 A5 JP WO2020160020A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- individual
- antibody
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025115594A JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797876P | 2019-01-28 | 2019-01-28 | |
| US62/797,876 | 2019-01-28 | ||
| US201962847826P | 2019-05-14 | 2019-05-14 | |
| US62/847,826 | 2019-05-14 | ||
| US201962861954P | 2019-06-14 | 2019-06-14 | |
| US62/861,954 | 2019-06-14 | ||
| US201962899094P | 2019-09-11 | 2019-09-11 | |
| US62/899,094 | 2019-09-11 | ||
| US201962931014P | 2019-11-05 | 2019-11-05 | |
| US62/931,014 | 2019-11-05 | ||
| EP19306554.7 | 2019-12-03 | ||
| EP19306554 | 2019-12-03 | ||
| US201962943716P | 2019-12-04 | 2019-12-04 | |
| US62/943,716 | 2019-12-04 | ||
| PCT/US2020/015455 WO2020160020A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115594A Division JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518060A JP2022518060A (ja) | 2022-03-11 |
| JPWO2020160020A5 true JPWO2020160020A5 (enExample) | 2023-02-22 |
| JP7712206B2 JP7712206B2 (ja) | 2025-07-23 |
Family
ID=69646031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543372A Active JP7712206B2 (ja) | 2019-01-28 | 2020-01-28 | 多発性骨髄腫の処置方法 |
| JP2025115594A Pending JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115594A Pending JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11939390B2 (enExample) |
| EP (2) | EP4588484A3 (enExample) |
| JP (2) | JP7712206B2 (enExample) |
| KR (1) | KR20210120048A (enExample) |
| CN (2) | CN114026121A (enExample) |
| AU (1) | AU2020215692A1 (enExample) |
| BR (1) | BR112021014699A2 (enExample) |
| CA (1) | CA3127928A1 (enExample) |
| CO (1) | CO2021011034A2 (enExample) |
| IL (2) | IL321343A (enExample) |
| MA (1) | MA54860A (enExample) |
| MX (1) | MX2021009079A (enExample) |
| SG (1) | SG11202108029XA (enExample) |
| TW (1) | TW202535952A (enExample) |
| WO (1) | WO2020160020A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015315006B2 (en) | 2014-09-12 | 2021-05-06 | The Regents Of The University Of California | Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics |
| EP4588484A3 (en) | 2019-01-28 | 2025-10-15 | Sanofi-Aventis U.S. LLC | Methods of treating multiple myeloma |
| BR112021022503A2 (pt) * | 2019-05-14 | 2021-12-28 | Sanofi Sa | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| IL293563A (en) * | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| US11484604B2 (en) * | 2020-08-07 | 2022-11-01 | Fortis Therapeutics, Inc. | Immunoconjugates targeting CD46 and methods of use thereof |
| IL302640A (en) * | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| CN114219787B (zh) * | 2021-12-17 | 2024-08-06 | 三峡大学 | 一种初诊多发性骨髓瘤预后分期系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP2520588A1 (en) | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP3741372A1 (en) * | 2012-08-09 | 2020-11-25 | Celgene Corporation | (s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione for use in the treatment of immune-related and inflammatory diseases |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| PL3294769T3 (pl) * | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| WO2016209921A1 (en) * | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US20180153989A1 (en) * | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| CN110869029A (zh) * | 2017-07-09 | 2020-03-06 | 拜欧赛特有限公司 | 组合癌症治疗 |
| EP4588484A3 (en) | 2019-01-28 | 2025-10-15 | Sanofi-Aventis U.S. LLC | Methods of treating multiple myeloma |
-
2020
- 2020-01-28 EP EP25172506.5A patent/EP4588484A3/en active Pending
- 2020-01-28 EP EP20706606.9A patent/EP3917961A1/en active Pending
- 2020-01-28 WO PCT/US2020/015455 patent/WO2020160020A1/en not_active Ceased
- 2020-01-28 BR BR112021014699A patent/BR112021014699A2/pt unknown
- 2020-01-28 SG SG11202108029XA patent/SG11202108029XA/en unknown
- 2020-01-28 MA MA054860A patent/MA54860A/fr unknown
- 2020-01-28 AU AU2020215692A patent/AU2020215692A1/en active Pending
- 2020-01-28 KR KR1020217027098A patent/KR20210120048A/ko active Pending
- 2020-01-28 US US16/775,025 patent/US11939390B2/en active Active
- 2020-01-28 CA CA3127928A patent/CA3127928A1/en active Pending
- 2020-01-28 CN CN202080024773.7A patent/CN114026121A/zh active Pending
- 2020-01-28 MX MX2021009079A patent/MX2021009079A/es unknown
- 2020-01-28 IL IL321343A patent/IL321343A/en unknown
- 2020-01-28 JP JP2021543372A patent/JP7712206B2/ja active Active
- 2020-01-28 CN CN202510783436.0A patent/CN120754030A/zh active Pending
- 2020-01-30 TW TW114114347A patent/TW202535952A/zh unknown
-
2021
- 2021-07-25 IL IL285110A patent/IL285110B2/en unknown
- 2021-08-23 CO CONC2021/0011034A patent/CO2021011034A2/es unknown
-
2024
- 2024-02-16 US US18/443,878 patent/US20240190984A1/en active Pending
-
2025
- 2025-07-09 JP JP2025115594A patent/JP2025148430A/ja active Pending